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Clonal chromosome anomalies and propensity
to myeloid malignancies in congenital
amegakaryocytic thrombocytopenia 
(OMIM 604498)
Congenital amegakaryocytic thrombocytopenia (CAMT,
OMIM 604498) is an autosomal recessive disorder charac-
terized by absent or reduced number of megakaryocytes in
the bone marrow (BM) since birth, elevated serum levels of
thrombopoietin (TPO), and very low platelet count.
Prognosis of CAMT patients is poor, because all develop in
childhood a tri-linear marrow aplasia that is always fatal
when untreated.1,2 Mutations of the MPL gene (OMIM
159530), coding for the TPO receptor,3 are responsible for
CAMT.4,5 We report the cytogenetic investigations and the
results of analysis by fluorescent in situ hybridization (FISH)
on 5 unrelated Italian patients whose clinical characteristics
and MPL gene mutations have already been reported.5
Three patients were females and two males, age at diagno-
sis ranging between 16 and 49 months. All children devel-
oped pancytopenia at an age comprised between 22 and 49
months. Patients’ designation (CAMT1-CAMT5 in Table 1)
is as in Savoia et al.5
Chromosome analyses were repeatedly performed on
BM and peripheral blood (PB) PHA-stimulated cultures
with routine methods. Skin fibroblasts (SF) were cultured
with routine methods in patient CAMT2. QFQ-banding
technique was used for all chromosome analyses. FISH
analyses on interphase nuclei were repeatedly performed
on all patients’ BM, on PB of CAMT4, and on SF of
CAMT2 with centromere-specific probes for chromo-
somes 7 (D7Z1), and 8 (D8Z2) (Cytocell Technologies,
Cambridge, UK) either with single fluorochromes or in
dual color combination. Nuclei from healthy subjects were
used as control.
All the results are detailed in Table 1. The karyotype was
consistently normal in patients CAMT1, CAMT3, and
CAMT5, and parallel FISH analysis on interphase nuclei
from BM confirmed the normal disomies 7 and 8. DEB test
performed on PB of CAMT1, CAMT2, and CAMT3
excluded Fanconi anemia (FA).
Patient CAMT2 progressed to pancytopenia, with nor-
mal BM and PB karyotype, at the age of 30 months
(January 2005), but in a subsequent analysis on BM, in
May 2006, trisomy 8 was found in 1 mitosis out of 24 and
5 nuclei out of 616. Analysis on fibroblasts from a skin
biopsy excluded a constitutional trisomy 8 mosaicism
(Table 1). In patient CAMT4, the karyotype was normal in
BM cells in 2001, at the age of 12 months, and in 2004
when progression to pancytopenia was observed, but in
May 2006 a BM clone with monosomy 7 was found which
persisted in the following analyses (Table 1). 
A risk of evolution into myelodysplastic syndrome
(MDS) and acute myeloid leukemia (AML) has often been
assumed for CAMT, but in a search for bona fide CAMT
patients who developed MDS/AML, we found only 3 such
cases in the literature, and none of these was proved to
carry mutations of the MPL gene: they are one refractory
anemia with excess of blasts (RAEB) reported by King et al.,2
and 2 cases mentioned by Alter,6 a male with acute
myelomonocytic leukemia (AMML) developed after an
aplastic anemia phase, and a female with a pre-leukemic
condition. These 2 latter cases were never reported in more
detail, and were studied some decades ago.6 In addition, a
report is available of a CAMT patient with MPL mutations
who developed a pre-B acute lymphoblastic leukemia.7
A review of CAMT cases with chromosome anomalies
is even more difficult to carry out since cytogenetic results
in the literature are often incorrectly mentioned, incom-
plete, and probably questionable. Among the patients with
MDS/AML mentioned above, clonal chromosome changes
in the BM were reported to be present in 2: the child with
RAEB2 with trisomy 21 in 10-15% of the cells, and the
patient with AMML6 with different anomalies of chromo-
some 19 (monosomy, trisomy, deletion) in 11 cells out of
55. As to CAMT without MDS/AML, King et al.2 reported
2 patients with possible chromosome anomalies in PB, but
the case identified as CAMT9 showed a translocation only
in one cell out of 19, whereas CAMT13 showed a super-
numerary marker (not better defined) in 94% of the cells.
The only case from the literature with a reliable clonal
anomaly in the BM was reported by Steele et al.,8 who
found monosomy 7 in 12 out of 20 mitoses and 91 out of
200 interphase nuclei. Mutations of the MPL gene were
identified in these 3 patients.4,8
In our 5 patients, BM clonal anomalies were found in 2, in
the absence of MDS/AML: one case of monosomy 7 and
one of trisomy 8; the latter was demonstrated not to be a
constitutional mosaicism, as is the case in 15-20% of
patients with MDS/AML and trisomy 8.9 While no exhaus-
tive cytogenetic study on CAMT is available, our small
group of patients was monitored over time for possible clon-
al chromosome anomalies in BM. We suggest that clonal
chromosome changes are frequently acquired in the BM of
CAMT patients: they often seem to be the most typical of
MDS, monosomy 7 and trisomy 8. Interestingly, in both our
patients the abnormal clones were found when the disease
had already progressed to pancytopenia (Table 1), and the
patient reported by Steele and co-workers showed mono-
somy 7 when CAMT had evolved to BM aplasia.8
In both our patients, the abnormal clone was detected
not at the first chromosome analysis but after and showed
a trend to expansion (Table 1). In particular, if we take into
account evaluations by interphase FISH, in patient
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CAMT2 the difference between BM samples of 23.05.06
and 06.07.06 only indicates this trend (0.02<p<0.05), while
in patient CAMT4 the difference between the BM samples
of 24.05.06 and 06.07.06 is significant (p<0.01).
The expansion of a BM clone with a chromosome
anomaly typical of MDS/AML, should be considered with
respect to the risk of hematologic malignancies in CAMT
patients. A plausible hypothesis is that a risk of progress-
ing into MDS/AML is really part of the CAMT phenotype,
although the short life expectancy and the use of
hematopoietic stem cell transplantation make it difficult to
demonstrate this evolution in most patients. If this is the
case, the patients with clonal anomalies might be those
who will progress to MDS/AML. We postulate that MPL
mutations might cause karyotype instability through a
mutator effect, with emergence of abnormal clones in the
BM possibly characterized by chromosome changes typi-
cal of MDS: this mechanism was suggested also for other
Mendelian BM failure syndromes, such as Shwachman
syndrome (SS), familial platelet disorder with propensity to
acute myeloid leukemia (FPD/AML, OMIM 601399), and
FA.10,11 In CAMT, the BM abnormal clone might stay qui-
escent even for long periods, as in SS, a full-blown MDS
picture being the consequence of its expansion. In conclu-
sion, we suggest that an appropriate cytogenetic follow-up
of BM should be part of the clinical management of
patients with CAMT, because the early detection of clonal
anomalies might be crucial for treatment choice.
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Table 1. Results of chromosome analyses and FISH on interphase nuclei.
Patient Date T/P1 Material2 Karyotype FISH on nuclei: D7Z1 probe, D8Z2 probe3
CAMT1 03.11.04 T BM 46,XX[20] D7Z1: 450/467 normal4 (96.3%); D8Z2: 557/571 normal (97%)
06.12.04 T PB-PHA 46,XX[100]
20.01.05 T PB-DEB 46,XX[100]
BM 46,XX[7] D7Z1: 450/458 normal (98.2%); D8Z2: 500/513 normal (97.4%)
CAMT2 11.01.05 T BM 46,XX[8]
PB-PHA 46,XX[100]
PB-DEB 46,XX[100]
18.11.05 T BM 46,XX[12]
23.05.06 P BM 47,XX,+8[1]/46,XX[23] D8Z2: 5/616 with trisomy 8 (0.8%)
06.07.06 P BM 47,XX,+8[5]/46,XX[22] D8Z2: 9/332 with trisomy 8 (2.7%)
SF 46,XX[56] D8Z2: 1314/1342 normal (97.9%) 
CAMT3 12.01.06 T PB-PHA 46,XY[100]
PB-DEB 46,XY[100]
BM 46,XY[22] D7Z1: 450/461 normal (97.6%); D8Z2: 400/415 normal (96.4%)
24.11.06 P BM 46,XY[35] D7Z1: 400/458 normal (98.2%); D8Z2: 500/515 normal (97%)
CAMT4 17.05.01 T BM 46,XY[67] D7Z1 + D8Z25: 390/400 normal (97.5%)
01.06.04 P BM 46,XY[26] D7Z1 + D8Z25: 11/400 with monosomy 7 (2.7%)
24.05.06 P BM 45,XY,-7[22] D7Z1 + D8Z25: 121/400 with monosomy 7 (30.2%)
30.08.06 P PB-PHA 46,XY[248] D7Z1 + D8Z25: 325/350 normal (92.9%)
06.07.06 P BM 45,XY,-7[55]/46,XY[4] D7Z1 + D8Z25: 161/400 with monosomy 7 (40.2%)
18.10.06 P BM 45,XY,-7[14]/46,XY[3]
04.01.07 BM 46,XY[16]6
CAMT5 14.03.02 T BM 46,XX[116] D7Z1 + D8Z25: 459/472 normal (97.2%)
14.05.02 P BM 46,XX[48] D7Z1 + D8Z25: 397/400 normal (99.5%)
02.10.03 P BM 46,XX[18]
1T: thrombocytopenia; P: evolution into pancytopenia; 2BM: bone marrow direct preparations and 24-48h cultures; PB-PHA: peripheral blood PHA stimulated culture;
PB-DEB: peripheral blood PHA stimulated cultures, with diepoxybutane (DEB); SF: skin fibroblast culture; 3FISH on normal controls showed an average of 97.2%
nuclei with two signals for D7Z1, and of 97.4% for D8Z2; 4normal result means that no evidence of monosomy 7 and of trisomy 8 was reached in the few nuclei not
showing two signals, with data comparable to controls; 5dual color FISH with probes D7Z1 and D8Z2; 6after hematopoietic stem cell transplantation. 
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Variability of clinical manifestation of factor 
VII-deficiency in homozygous and heterozygous
subjects of the European F7 gene mutation A294V
Inherited factor VII deficiency (FVIID) is a rare autoso-
mal bleeding disorder. Subjects with reduced FVII activity
and identified F7 gene mutation are registered in the
International Greifswald registry of FVIID.1 The mutation
A294V is the most frequent among 717 FVIID patients in
Central and North-Eastern Europe. The high prevalence
of FVIID homozygous and heterozygous subjects, who
share the same mutation (A294V), offers the unique pos-
sibility to study the clinical variability in a relatively large
number of individuals with the identical defect in the F7
gene. In the reported study we have analyzed the clinical
variability of 14 homozygous and 99 heterozygous sub-
jects with F7 gene mutation A294V. Subjects with combi-
nations with other bleeding disorders such as von
Willebrand Disease, deficiency of FIX, FII etc., were
excluded.
We collected data on factor VII clotting (FVII:C) activi-
ty, FVII antigen (FVII:Ag), date of initial onset of bleeding
and bleeding symptoms.1,2
FVII:C was assayed locally with standard one-stage
methods using thromboplastin (mostly recombinant and
human-derived, Thromborel S® Dade Behring). FVII:Ag
was measured at some of the centers using an immunoen-
zymatic method (Asserachrom, Diagnostica Stago,
Asnieres, France). The following bleeding symptoms
were evaluated according to published criteria:1-4 intracra-
nial hemorrhage (ICH), gastrointestinal (GI) hemorrhage,
hemarthrosis, subcutaneous hematoma as well as epis-
taxis, oral bleeding, and menorrhagia in accordance with
Peyvandi and Mannucci.5 Endogenous thrombin potential
(ETP) was measured in platelet poor plasma from controls
and subjects homozygous for A294V in the presence of
activated protein C.6 Citrated plasma samples from 8 con-
trol subjects without FVLeiden or FVHR2 (factor V wild type;
FVwt) and without A294V mutation were used as a refer-
ence. We used the mutation H1299R as marker for
FVHR2.7 The FVLeiden mutation was determined according
to Bertina et al.8
The 14 homozygous subjects for the F7 gene mutation
A294V are characterized by mean levels of FVII:C of
10±6% and of FVII:Ag of 52±11%. Nine of the homozy-
gous patients (64%) had spontaneous bleeding symptoms
(classified as symptomatic) and 5 (36%) did not (classified
as asymptomatic). There was no significant difference in
FVII level between symptomatic and asymptomatic
homozygous A294V subjects.
The spontaneous bleeding profile of the 9 symptomatic
subjects was characterized by GI (22%) bleeds,
hemarthrosis (22%), epistaxis (33%), easy bruising (11%),
gingival bleeding (22%), subcutaneous hematoma (11%),
Table 1. Endogenous thrombin potential, bleeding symptoms and co-inheritance of FVHR2 in nine patients homozygous for the mutation
A294V with available plasma samples. 
Endogenous thrombin potential
compared to the references
reference (100%)
G-9125 6 8 hz asympt. 203%
G-9297 18 25 ho asympt. 146%
G-9130 15 4 wt mild 93%
G-9623 32 8 hz mild 82%
G-13255 10 7 wt mild 59%
G-9773 59 6 wt moderate 56%
G-13325 74 11 wt severe 65%
G-12990 44 9 wt severe 57%
G-10833 57 3 wt severe 47%
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